Global Information
회사소개 | 문의 | 비교리스트

각막혈관신생 : 파이프라인 리뷰

Corneal Neovascularization - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 246015
페이지 정보 영문 41 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


각막혈관신생 : 파이프라인 리뷰 Corneal Neovascularization - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 41 Pages

각막혈관신생이란 산소 결핍 및 스트레스가 원인으로 일반적으로 반투명인 각막에 혈관이 이상 증식하는 상태입니다. 소인으로 감염증, 눈의 외상, 화학 화상, 면역계 질환, 포도막염 및 녹내장 등 특정 눈의 증상 등이 있습니다. 증상은 눈의 염증, 안구건조증, 전염성 결막염 및 결막염, 광감수성 등입니다.

세계 각국에서의 각막혈관신생 치료용 파이프라인 제품의 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계별 제품 리스트, 주요 기업의 개요, 주요 약제 개요(제품 개요, 기능 메커니즘, R&D 진전 상황), 최신 업계 동향 등을 조사하여 전해드립니다.

서론

  • 조사 범위

각막혈관신생 개요

치료제 개발

  • 파이프라인 제품의 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

각막혈관신생 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

각막혈관신생 치료제 개발에 참여하고 있는 기업

  • Amakem NV
  • EyeGate Pharmaceuticals Inc
  • Gene Signal International SA

약제 개요

각막혈관신생 : 휴지중인 프로젝트

각막혈관신생 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Corneal Neovascularization, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Corneal Neovascularization - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
  • Corneal Neovascularization - Pipeline by EyeGate Pharmaceuticals Inc, H1 2020
  • Corneal Neovascularization - Pipeline by FortuneRock (China) Ltd, H1 2020
  • Corneal Neovascularization - Pipeline by Gene Signal International SA, H1 2020
  • Corneal Neovascularization - Pipeline by Singh Biotechnology LLC, H1 2020
  • Corneal Neovascularization - Pipeline by Wntgen LLC, H1 2020
  • Corneal Neovascularization - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Corneal Neovascularization, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Pipeline Review, H1 2020, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape.

Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Corneal Neovascularization - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Corneal Neovascularization - Overview
    • Corneal Neovascularization - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Corneal Neovascularization - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Corneal Neovascularization - Companies Involved in Therapeutics Development
    • Chengdu Kanghong Pharmaceuticals Group Co Ltd
    • EyeGate Pharmaceuticals Inc
    • FortuneRock (China) Ltd
    • Gene Signal International SA
    • Singh Biotechnology LLC
    • Wntgen LLC
  • Corneal Neovascularization - Drug Profiles
    • aganirsen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Corneal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit VEGF-A for Corneal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDE-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KH-906 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins for Oncology and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBT-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SFR-9X0122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Wnt-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Corneal Neovascularization - Dormant Projects
  • Corneal Neovascularization - Product Development Milestones
    • Featured News & Press Releases
      • May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation.
      • Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure
      • Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
      • Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q